
Academic Journal
Q3Journal of Cancer Metastasis and Treatment
About Journal of Cancer Metastasis and Treatment
About Journal of Cancer Metastasis and Treatment
Journal of Cancer Metastasis and Treatment is a peer-reviewed scholarly journal published by OAE Publishing Inc. (United States). It focuses on Q3. Publication coverage spans 2019-2025.
Key indicators: ISSN 2394-4722, 2454-2857; H-index 21.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (21): 21 articles have each received at least 21 citations, indicating growing recognition.
Publishing in Journal of Cancer Metastasis and Treatment
When considering this journal, verify its current indexing status, editorial board, and recent publications to ensure it meets your needs for visibility and credibility.
- Scope fit: Confirm your research aligns with Q3. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
- Submission: Submit via the official journal website.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Journal of Cancer Metastasis and Treatment?
2394-4722, 2454-2857.
Who publishes Journal of Cancer Metastasis and Treatment?
OAE Publishing Inc..
What are Journal of Cancer Metastasis and Treatment's metrics?
H-index 21.
Where do I submit to Journal of Cancer Metastasis and Treatment?
Via the official website.
Is Journal of Cancer Metastasis and Treatment peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Cancer Cells and Metastasis; Cancer Immunotherapy and Biomarkers; Cancer Genomics and Diagnostics; Cancer Diagnosis and Treatment; Lung Cancer Research Studies; Cancer Research and Treatments.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Feature interview with Dr. William C. Cho - “Clarivate 2023 highly cited researcher”
Frida Xu
2024 · DOI: 10.20517/2394-4722.2024.04Research advances in immunotherapy combined with DNA damage response inhibitors for liver cancer therapy
Chen Yang, Tao Tao, Yijie Wu, Weijie Wang et al.
2024 · DOI: 10.20517/2394-4722.2023.175Integration of community pharmacies in an Italian colorectal cancer screening program: insights from the Local Health Authority of Bologna
Angela Chiereghin, Lorenzo Pizzi, Tiziana Sanna, Lorena Squillace et al.
2024 · DOI: 10.20517/2394-4722.2023.118Clinical resistance predictors to first-line VEGFR-TKI monotherapy for metastatic renal cell carcinoma: a retrospective multicenter real-life case series
Pezzicoli Gaetano, Quaglini Silvana, Tibollo Valentina, Bersanelli Melissa et al.
2023 · DOI: 10.20517/2394-4722.2023.41Role of epithelial-mesenchymal transition factor SNAI1 and its targets in ovarian cancer aggressiveness
Tise Suzuki, Ashlyn Conant, Casey Curow, Audrey Alexander et al.
2023 · DOI: 10.20517/2394-4722.2023.34Tricking the tumour microenvironment into becoming our best rational drug design factory: reversal of immune suppression
Martin L. Ashdown
2022 · DOI: 10.20517/2394-4722.2022.01Diffuse large B-Cell lymphoma: from novel molecular classifications to tailored targeted therapies
Jennifer K. Lue, Grzegorz S. Nowakowski
2022 · DOI: 10.20517/2394-4722.2021.193Moving towards the chemo-free treatment of lymphoma: hype or reality?
Bruce D. Cheson
2022 · DOI: 10.20517/2394-4722.2021.153Serum squamous cell carcinoma antigen is a predictive factor of outcomes in patients with locally advanced unresectable esophageal squamous cell carcinoma treated by definitive chemoradiotherapy
Takeshi Suzuki, Akihiko Okamura, Masayuki Watanabe, Takao Asari et al.
2022 · DOI: 10.20517/2394-4722.2021.160The role of radiotherapy in metastatic bladder cancer
Jananie Perera, Peter Hoskin
2022 · DOI: 10.20517/2394-4722.2021.167Combined effects of oncolytic vaccinia virus and dendritic cells on the progression of melanoma B16-F10 in mice
Elena P. Goncharova, Tatiana A. Gamburg, Oleg V. Markov, Marina A. Zenkova et al.
2022 · DOI: 10.20517/2394-4722.2021.195The role of MT1-MMP in the progression and metastasis of osteosarcoma
Hannah L. M. Spencer, Steven D. Shnyder, Paul M. Loadman, Robert A. Falconer et al.
2022 · DOI: 10.20517/2394-4722.2021.174The bone marrow niche landscape: a journey through aging, extrinsic and intrinsic stressors in the haemopoietic milieu
Antonio Giovanni Solimando, Assunta Melaccio, Angelo Vacca, Roberto Ria et al.
2022 · DOI: 10.20517/2394-4722.2021.166Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells
Donald W. Kufe
2022 · DOI: 10.20517/2394-4722.2022.03New developments in management of metastatic thyroid cancer
Jerome M. Hershman
2022 · DOI: 10.20517/2394-4722.2021.156Diverse roles of bitter melon (<i>Momordica charantia</i>) in prevention of oral cancer
Subhayan Sur, Ratna B. Ray
2021-03-09 · DOI: 10.20517/2394-4722.2020.126Seaweeds’ nutraceutical and biomedical potential in cancer therapy: a concise review
João Cotas, Diana Pacheco, Ana M. M. Gonçalves, Paulo Silva et al.
2021-03-09 · DOI: 10.20517/2394-4722.2020.134Management of lung cancer in the COVID-19 pandemic: a review
Fernando Maroto Piñeiro, Carmen Trinidad López, Javier De la Fuente Aguado
2021-02-07 · DOI: 10.20517/2394-4722.2020.115Proximal humerus reconstruction in orthopedic oncology
Sridhar Pinnamaneni, Timothy A. Damron
2021-02-03 · DOI: 10.20517/2394-4722.2020.94Immuno-oncology in triple-negative breast cancer
Anne-Sophie Heimes, Marcus Schmidt
2021-02-03 · DOI: 10.20517/2394-4722.2020.124Reviews
Community Reviews
Version History
October 10, 2026 at 6:36 am
October 2, 2026